Disease · MONDO_0006485

uterine carcinosarcoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. uterine carcinosarcoma. Diseases, record MONDO_0006485. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006485

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: uterine carcinosarcoma; Open Targets
Open Targets ID: MONDO_0006485; Open Targets
Other names: carcinosarcoma of the uterus, malignant mixed mesodermal (Mullerian) tumor of the uterus, malignant mixed mesodermal (Mullerian) tumour of the uterus, malignant mixed mesodermal (Müllerian) tumor of the uterus, malignant mixed mesodermal (Müllerian) tumour of the uterus, mixed mullerian sarcoma of uterus, uterine malignant mixed mesodermal (Mullerian) tumor, uterine malignant mixed mesodermal (Mullerian) tumour, uterine malignant mixed mesodermal (Müllerian) tumor, uterine malignant mixed mesodermal (Müllerian) tumour, uterus carcinosarcoma; Open Targets
Disease Ontology: DOID:6171; Disease Ontology
MeSH: D012192; MeSH
NCI Thesaurus: C42700; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 3 of its 22 drugs, from ClinicalTrials.gov; Open Targets

Drugs22

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
IFOSFAMIDE	CHEMBL1024	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
GEMCITABINE	CHEMBL888	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
NIVOLUMAB	CHEMBL2108738	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
ADAVOSERTIB	CHEMBL1976040	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DOCETAXEL	CHEMBL3545252	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DURVALUMAB	CHEMBL3301587	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 22

See all 22 drugs

Targets57

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
FLT1	Vascular endothelial growth factor receptor	4	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	4	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2324	Drugs and targets
KDR	Vascular endothelial growth factor receptor	4	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets
TUBA1A	Tubulin	4	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	4	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	4	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	4	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	4	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	4	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	4	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/203068	Drugs and targets

1 to 10 of 57

See all 57 targets

Trials19

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00954174	Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer	Phase 3	637	2020-08-10	Mixed Mesodermal (Mullerian) Tumor, Ovarian Carcinosarcoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage I Ovarian Cancer AJCC v6 and v7, Stage IA Fallopian Tube Cancer AJCC v6 and v7, Stage IA Ovarian Cancer AJCC v6 and v7, Stage IA Uterine Sarcoma AJCC v7, Stage IB Fallopian Tube Cancer AJCC v6 and v7, Stage IB Ovarian Cancer AJCC v6 and v7, Stage IB Uterine Sarcoma AJCC v7, Stage IC Fallopian Tube Cancer AJCC v6 and v7, Stage IC Ovarian Cancer AJCC v6 and v7, Stage IC Uterine Sarcoma AJCC v7, Stage II Ovarian Cancer AJCC v6 and v7, Stage IIA Fallopian Tube Cancer AJCC v6 and v7, Stage IIA Ovarian Cancer AJCC V6 and v7, Stage IIA Uterine Sarcoma AJCC v7, Stage IIB Fallopian Tube Cancer AJCC v6 and v7, Stage IIB Ovarian Cancer AJCC v6 and v7, Stage IIB Uterine Sarcoma AJCC v7, Stage IIC Fallopian Tube Cancer AJCC v6 and v7, Stage IIC Ovarian Cancer AJCC v6 and v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIA Uterine Sarcoma AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIB Uterine Sarcoma AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IIIC Uterine Sarcoma AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7, Stage IVA Uterine Sarcoma AJCC v7, Stage IVB Uterine Sarcoma AJCC v7, Uterine Carcinosarcoma	CARBOPLATIN, IFOSFAMIDE, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT00238121	Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer	Phase 2	56	2014-06-10	Recurrent Uterine Sarcoma, Stage III Uterine Sarcoma, Stage IV Uterine Sarcoma, Uterine Carcinosarcoma	SORAFENIB	Its record names the disease	ClinicalTrials.gov
NCT00025506	Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus	Phase 2	55	2015-05-27	Recurrent Uterine Corpus Sarcoma, Uterine Carcinosarcoma	THALIDOMIDE	Its record names the disease	ClinicalTrials.gov
NCT00112489	Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer	Phase 2	55	2014-05-12	Sarcoma	CARBOPLATIN, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT04439214	Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)	Phase 2	47	2021-04-06	Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Plasma Cell Myeloma	NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT01168232	Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer	Phase 2	42	2017-01-23	Recurrent Uterine Corpus Sarcoma, Uterine Carcinosarcoma	IXABEPILONE	Its record names the disease	ClinicalTrials.gov
NCT00231842	Adjuvant Radiation Therapy With Ifosfamide in Patients With Mixed Mesodermal Tumors of the Uterus	Phase 2	30	2019-01-23	Uterine Cancer	CISPLATIN, IFOSFAMIDE	Its record names the disease	ClinicalTrials.gov
NCT00114218	Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer	Phase 2	28	2018-10-16	Recurrent Uterine Corpus Sarcoma, Uterine Carcinosarcoma	DOCETAXEL, GEMCITABINE	Its record names the disease	ClinicalTrials.gov
NCT03206177	Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary	Phase 1	26	2024-08-07	Carcinosarcoma, Ovarian	CARBOPLATIN, GALUNISERTIB, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT01247571	Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer	Phase 2	22	2017-07-27	Recurrent Uterine Corpus Sarcoma, Uterine Carcinosarcoma	PAZOPANIB HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 19

See all 19 trials

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Regimen I - Uterine and Non-uterine Carcinosarcoma vs Regimen II - Uterine and Non-uterine Carcinsarcoma Subjects: deaths from any cause	160 of 272	160 of 267	539	NCT00954174	Trial comparisons
Regimen I - Uterine and Non-uterine Carcinosarcoma vs Regimen II - Uterine and Non-uterine Carcinsarcoma Subjects: serious adverse events	80 of 268	68 of 247	515	NCT00954174	Trial comparisons
Carcinoma vs Carcinosarcoma: Objective Overall Response Rate	2 of 37	0 of 14	51	NCT00238121	Trial comparisons

Papers from its trials9

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
31765263	RESULT	1	PubMed
22055846	RESULT	1	PubMed
20421537	RESULT	1	PubMed
15975641	RESULT	1	PubMed
41231502	DERIVED	1	PubMed
40608313	DERIVED	1	PubMed
35007153	DERIVED	1	PubMed
33705205	DERIVED	1	PubMed
22634397	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006485

GET https://conductscience.org/api/diseases/v1/MONDO_0006485/drugs?page=2

API reference For AI assistants